Somewhat Positive News Coverage Somewhat Unlikely to Impact Sage Therapeutics (SAGE) Share Price
Media stories about Sage Therapeutics (NASDAQ:SAGE) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sage Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7103916284449 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Watching Historical Performance for Sage Therapeutics, Inc. (NASDAQ:SAGE) – Jonesboro Recorder (jonesbororecorder.com)
- Stocks in the Limelight: Sage Therapeutics, Inc. (NASDAQ:SAGE), Churchill Downs Incorporated (NASDAQ:CHDN) – FLBC News (flbcnews.com)
- Kylie Jenner accidentally shows her breast implants! (fumbleboard.com)
- Sage Therapeutics Reaches Analyst Target Price (nasdaq.com)
- Dustin Johnson finds room for improvement despite shooting third round 64 (techzolix.com)
Sage Therapeutics (NASDAQ:SAGE) opened at 84.27 on Wednesday. The stock’s market capitalization is $3.15 billion. Sage Therapeutics has a 12-month low of $35.02 and a 12-month high of $88.93. The stock’s 50 day moving average is $79.56 and its 200 day moving average is $67.52.
Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.61) by $0.09. Analysts forecast that Sage Therapeutics will post ($6.76) EPS for the current year.
Several equities analysts have weighed in on the stock. Leerink Swann reiterated an “outperform” rating and set a $97.00 price objective (up from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. Stifel Nicolaus reiterated a “buy” rating and set a $90.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 14th. BidaskClub upgraded shares of Sage Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 13th. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Sage Therapeutics in a research report on Tuesday, June 13th. Finally, Cowen and Company assumed coverage on shares of Sage Therapeutics in a research report on Monday, June 12th. They set an “outperform” rating and a $95.00 price objective on the stock. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Sage Therapeutics presently has a consensus rating of “Buy” and an average price target of $85.82.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.